Monoclonal Antibody KI-67 Defined Growth Fraction in Benign Prostatic Hyperplasia and Prostatic Cancer

Abstract

No AccessJournal of Urology1 Nov 1989Monoclonal Antibody KI-67 Defined Growth Fraction in Benign Prostatic Hyperplasia and Prostatic Cancer M.P.W. Gallee, E. Visser-De Jong, F. J. W. Ten Kate, F.H. Schroeder, and Th. H. Van Der Kwast M.P.W. GalleeM.P.W. Gallee , E. Visser-De JongE. Visser-De Jong , F. J. W. Ten KateF. J. W. Ten Kate , F.H. SchroederF.H. Schroeder , and Th. H. Van Der KwastTh. H. Van Der Kwast View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)39094-8AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Growth fractions were assessed immunohistochemically in prostatic tissues with benign glandular hyperplasia (BPH) and in specimens of prostatic cancer using the monoclonal antibody Ki-67. This antibody is specific for a proliferation-associated nuclear antigen. In BPH tissues about 0.3% of nuclei of epithelial cells was reactive with Ki-67. The Ki-67 positive nuclei were distributed equally among the basal and luminal cells of the hyperplastic prostatic acini. In prostatic cancer the Ki-67 defined growth fraction ranged from 0.4% to 9.1% (mean value 2.9%). Cancers with a cribriform growth pattern and tumors composed of solid areas of undifferentiated cancer cells showed the highest growth fraction (average values 4.0%, respectively 7.6%). The investigated four tumors composed of undifferentiated solitary tumor cells with diffuse infiltration of the stroma demonstrated an unexpectedly low growth activity (average 1.2%). In cancers with a glandular growth pattern the Ki-67 defined growth fraction of tumor cells varied from 2.2% to 5%. Compared with other epithelial tumors these values are low, but they are in agreement with the earlier findings on prostatic cancer obtained with 3H-thymidine labeling and bromodeoxyuridine incorporation. The observed variation in the level of Ki-67 defined growth activity partly related to the histological tumor pattern suggests that Ki-67 labeling may serve as a prognostic factor additional to the current histopathological grading criteria of prostatic cancer. (J. Urol., 142: 1342–1346, 1989) © 1989 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited ByBORRE M, BENTZEN S, NERSTROM B and OVERGAARD J (2018) TUMOR CELL PROLIFERATION AND SURVIVAL IN PATIENTS WITH PROSTATE CANCER FOLLOWED EXPECTANTLYJournal of Urology, VOL. 159, NO. 5, (1609-1614), Online publication date: 1-May-1998.Connolly J, Presti J, Cher M, Chew K, Shinohara K and Carroll P (2018) Accelerated Tumor Proliferation Rates in Locally Recurrent Prostate Cancer After Radical ProstatectomyJournal of Urology, VOL. 158, NO. 2, (515-518), Online publication date: 1-Aug-1997.Bettencourt M, Bauer J, Sesterhenn I, Mostofi F, McLeod D and Moul J (2018) Ki-67 Expression is a Prognostic Marker of Prostate Cancer Recurrence after Radical ProstatectomyJournal of Urology, VOL. 156, NO. 3, (1064-1068), Online publication date: 1-Sep-1996.Cher M, Stephenson R, James B and Carroll P (2018) Cellular Proliferative Fraction of Metastatic Lymph Nodes Predicts Survival in Stage D1 (TxN+MO) Prostate CancerJournal of Urology, VOL. 155, NO. 5, (1674-1677), Online publication date: 1-May-1996.Oomens E, Van Steenbrugge G, Van Der Kwast T and Schröder F (2018) Application of the Monoclonal Antibody Ki-67 on Prostate Biopsies to Assess the Proliferative Cell Fraction of Human Prostatic CarcinomaJournal of Urology, VOL. 145, NO. 1, (81-85), Online publication date: 1-Jan-1991. Volume 142Issue 5November 1989Page: 1342-1346 Advertisement Copyright & Permissions© 1989 by The American Urological Association Education and Research, Inc.MetricsAuthor Information M.P.W. Gallee More articles by this author E. Visser-De Jong More articles by this author F. J. W. Ten Kate More articles by this author F.H. Schroeder More articles by this author Th. H. Van Der Kwast More articles by this author Expand All Advertisement PDF DownloadLoading ...